| The EUROclass trial: defining subgroups in common variable immunodeficiency C Wehr, T Kivioja, C Schmitt, B Ferry, T Witte, E Eren, M Vlkova, ... Blood, The Journal of the American Society of Hematology 111 (1), 77-85, 2008 | 940 | 2008 |
| Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma BA Walker, EM Boyle, CP Wardell, A Murison, DB Begum, NM Dahir, ... Journal of clinical oncology 33 (33), 3911-3920, 2015 | 617 | 2015 |
| The SCUBA HAlf Degree Extragalactic Survey–III. Identification of radio and mid-infrared counterparts to submillimetre galaxies RJ Ivison, TR Greve, JS Dunlop, JA Peacock, E Egami, I Smail, E Ibar, ... Monthly Notices of the Royal Astronomical Society 380 (1), 199-228, 2007 | 390 | 2007 |
| APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma BA Walker, CP Wardell, A Murison, EM Boyle, DB Begum, NM Dahir, ... Nature communications 6 (1), 6997, 2015 | 332 | 2015 |
| Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial GH Jackson, FE Davies, C Pawlyn, DA Cairns, A Striha, C Collett, ... The Lancet Oncology 20 (1), 57-73, 2019 | 324 | 2019 |
| Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international … I Roberts, H Shakur-Still, A Afolabi, A Akere, M Arribas, A Brenner, ... The Lancet 395 (10241), 1927-1936, 2020 | 303 | 2020 |
| Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients V Shah, AL Sherborne, BA Walker, DC Johnson, EM Boyle, S Ellis, ... Leukemia 32 (1), 102-110, 2018 | 233 | 2018 |
| Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma? C Pawlyn, L Fowkes, S Otero, JR Jones, KD Boyd, FE Davies, GJ Morgan, ... Leukemia 30 (6), 1446-1448, 2016 | 152 | 2016 |
| andJ JR Jones, DM Parrott N. Perry, 225-252, 1981 | 145 | 1981 |
| Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control C Pawlyn, MD Bright, AF Buros, CK Stein, Z Walters, LI Aronson, ... Blood cancer journal 7 (3), e549-e549, 2017 | 113 | 2017 |
| The spectrum and clinical impact of epigenetic modifier mutations in myeloma C Pawlyn, MF Kaiser, C Heuck, L Melchor, CP Wardell, A Murison, ... Clinical cancer research 22 (23), 5783-5794, 2016 | 102 | 2016 |
| Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial JR Jones, DA Cairns, WM Gregory, C Collett, C Pawlyn, R Sigsworth, ... Blood cancer journal 6 (12), e506-e506, 2016 | 91 | 2016 |
| Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated … JR Jones, N Weinhold, C Ashby, BA Walker, C Wardell, C Pawlyn, ... Haematologica 104 (7), 1440, 2019 | 83 | 2019 |
| The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial C Pawlyn, D Cairns, M Kaiser, A Striha, J Jones, V Shah, M Jenner, ... Leukemia 34 (2), 604-612, 2020 | 77 | 2020 |
| Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials CA Bradbury, Z Craig, G Cook, C Pawlyn, DA Cairns, A Hockaday, ... Blood, The Journal of the American Society of Hematology 136 (9), 1091-1104, 2020 | 73 | 2020 |
| Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the phase III myeloma XI study GH Jackson, FE Davies, C Pawlyn, DA Cairns, A Striha, C Collett, ... Blood 128 (22), 1143, 2016 | 54 | 2016 |
| Secondary HLH is uncommon in severe COVID‐19 H Wood, JR Jones, K Hui, T Mare, T Pirani, J Galloway, V Metaxa, ... British journal of haematology 190 (5), e283, 2020 | 51 | 2020 |
| Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI … GH Jackson, FE Davies, C Pawlyn, DA Cairns, A Striha, C Collett, ... The Lancet Haematology 6 (12), e616-e629, 2019 | 50 | 2019 |
| Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the myeloma XI trial G Jackson, FE Davies, C Pawlyn, D Cairns, A Striha, A Hockaday, ... Blood 130, 436, 2017 | 46 | 2017 |
| Tendon implantation into bone: an experimental study JR Jones, JG Smibert, CJ McCullough, AB Price, WC Mutton The Journal of Hand Surgery: British & European Volume 12 (3), 306-312, 1987 | 46 | 1987 |
